Association between financial toxicity and health-related quality of life of patients with gynecologic cancer

[1] Thurgar E(2021)Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer J Med Econ 24 675-688

[2] Gouldson M(2015)Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study J Oncol Pract 11 145-150

[3] Matthijsse S(2021)Financial toxicity during breast cancer treatment: a qualitative analysis to inform strategies for mitigation JCO Oncol Pract 17 1413-1423

[4] Zafar SY(2013)The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience Oncologist 18 381-390

[5] McNeil RB(2019)Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer J Glob Oncol 5 1-8

[6] Thomas CM(2020)Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life Ann Oncol 31 96-102

[7] Gharzai LA(2022)Association of self-reported financial burden with quality of life and oncologic outcomes in head and neck cancer Head Neck 44 412-419

[8] Ryan KA(2022)Validation of Korean version of the COmprehensive Score for financial Toxicity (COST) among breast cancer survivors Cancer Res Treat 54 834-841

[9] Szczygiel L(2022)Validity of the COmprehensive Score for Financial Toxicity (COST) in patients with gynecologic cancer Int J Gynecol Cancer 27 2224-2229

[10] Zafar SY(2016)The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy Ann Oncol 17 377-387

[1] Thurgar E(2021)Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer J Med Econ 24 675-688

[2] Gouldson M(2015)Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study J Oncol Pract 11 145-150

[3] Matthijsse S(2021)Financial toxicity during breast cancer treatment: a qualitative analysis to inform strategies for mitigation JCO Oncol Pract 17 1413-1423

[4] Zafar SY(2013)The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience Oncologist 18 381-390

[5] McNeil RB(2019)Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer J Glob Oncol 5 1-8

[6] Thomas CM(2020)Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life Ann Oncol 31 96-102

[7] Gharzai LA(2022)Association of self-reported financial burden with quality of life and oncologic outcomes in head and neck cancer Head Neck 44 412-419

[8] Ryan KA(2022)Validation of Korean version of the COmprehensive Score for financial Toxicity (COST) among breast cancer survivors Cancer Res Treat 54 834-841

[9] Szczygiel L(2022)Validity of the COmprehensive Score for Financial Toxicity (COST) in patients with gynecologic cancer Int J Gynecol Cancer 27 2224-2229

[10] Zafar SY(2016)The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy Ann Oncol 17 377-387